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Phylogenetic analysis of 166 human parvovirus B19 sequences from 11 different countries attributed 91.57%
to genotype 1, 5.42% to genotype 3b, and 3.01% to genotype 3a. Very similar viruses of genotype 1 circulated
widely in Europe and Israel. Genotype 3b seems to show an increasing spread outside of Africa.
Human parvovirus B19 (B19V) infections are usually asso-
ciated with mild disease, but in immunocompromised and ane-
mic patients, as well as during pregnancy, severe complications
can occur. Based on the genetic variability of 994 nucleotides
(nt) of the NS1/VP1-unique region junction, three distinct
genotypes of B19V have been proposed (13). A recent report
presented evidence that certain complications might be pref-
erentially associated with certain virus genotypes (6). Several
studies demonstrated that previously published or commer-
cially available assays show differences in their diagnostic per-
formance, including the inability to detect certain genotypes,
especially genotype 3, subtype 3b (1, 5). Despite these impor-
tant implications for the diagnosis of B19V, little is known
about the genotypes prevalent in many countries.
Serum samples collected between 2000 and 2008 mostly
from rash/fever patients negative for both measles and rubella
from 11 different countries were analyzed for B19V (Table 1).
A nested PCR was performed with the forward primers e1855f
and e1863f (13) and reverse primers B19-R1 (5-GGGAACT
TCCGGCAAACTTCCTTG-3) and B19-R2 (5-GTAGTCTT
TTACTACTTGTGCTTG-3), yielding fragments of 1,239 and
1,168 nt. Previously published reverse primers (13) have a
maximum of three (e2953r) and four (e2960r) mismatches
compared to B19V GenBank sequences, including 3 and 5
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12 1–21 2006–2007 12 1.07
Osh, Kyrgyzstan 12 1–29b 2006–2007 8 4 5.95
Bulgaria 54 3–39 2005–2007 53 1 0.54
Burkina Faso 5 20–29 2007–2008 5 0.41
Estonia 8 4–17 2008 8 0.66
Georgia 3 1–14 2008 3 0.27
Greece 21 13–44b 2000–2005 20 1 1.77
Israel 14 7–66 2001–2006 14 0.52
Luxembourg 21 7–58 2000–2006 21 0.81
Nigeria 5 5–69 2005, 2007 2 3 7.3
Russia 5 1–38 2006–2007 5 0.41
Serbia 6 3–31 2007 6 0.34
Total 166 1–69b 2000–2008 152 5 9 2.48
a Distance between all sequences from the same location.
b Age not recorded for all patients.
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FIG. 1. (a) Phylogenetic tree based on 319 sequences (166 obtained in this study and 153 downloaded from GenBank). The basis of each
isosceles triangle is proportional to the number of sequences. (b) Phylogenetic tree based on 92 nonredundant sequences from this study and a
set of sequences downloaded from GenBank used as references for the different genotypes. The reference sequences are shown without symbols
and are labeled with their GenBank accession number, name, and genotype designation. Phylogenetic analyses are based on a region of 994 nt and
the neighbor-joining algorithm using the Kimura two-parameter model. Sequences are from 12 different locations in 11 countries: Bishkek,
Kyrgyzstan (black circles); Osh, Kyrgyzstan (dark gray circles); Bulgaria (light gray circles); Burkina Faso (black squares); Estonia (dark gray
squares); Georgia (light gray squares); Greece (black triangles); Israel (dark gray triangles); Luxembourg (inverted black triangles); Nigeria
(inverted dark gray triangles); the Russian Federation (black diamonds); and Serbia (dark gray diamonds).
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mismatches. Considering the impact of mismatches in the
primer binding sites (7), our new reverse primers with no more
than two mismatches would be more sensitive to amplify the
NS1/VP1-unique region junction proposed for genotyping by
sequencing and phylogenetic analysis (13).
Phylogenetic analysis (MEGA version 3.1) of 166 sequences
obtained in this study (Table 1) and 153 sequences downloaded
from GenBank (February 2009) showed that the majority of
the new samples (n  152 [91.57%]) and 245 sequences in total
clustered together to form the genotype 1 group, including two
outliers (DQ357064 and DQ357065) (Fig. 1a). Genotype 1
dominated in 9 of the 11 countries investigated here. Thus, our
results further confirm the predominance of genotype 1 in
most parts of the world (15). The mean genetic distance among
all genotype 1 sequences within the 994-nt region was 0.91%,
and the maximal genetic distance was 4.70% (DQ357065 and
DQ293995).
Recent studies suggest that genotype 2 viruses circulated
widely in Europe half a century ago, before they were largely
replaced by genotype 1 (6, 9). Not a single genotype 2 virus was
found in this study, further indicating that this genotype has
essentially disappeared from circulation (9). Thirty-eight of the
39 sequences from GenBank attributed to genotype 2 clustered
together, while one sequence (DQ333427) seems to represent
an outlier of genotype 2 (Fig. 1a). The genotype 2 sequences
exhibited an overall mean genetic distance of 1.17% and a
maximal genetic distance of 4.71% (DQ333427 and
AY064476).
The 35 sequences belonging to genotype 3, including the 14
new sequences (5 subtype 3a and 9 subtype 3b) described here,
grouped together with a bootstrap support of 100%. All se-
quences except two identical outliers (AJ249421 and
AY083237) fell into the two groups previously designated as
genotypes 3a (n  12) and 3b (n  21) (10). Within genotype
3a, two clusters supported by bootstrap values of 94 and 88
could be distinguished, and within 3b, three main clusters
(bootstrap values 78, 90, and 75) were observed (Fig. 1a). The
genotype 3 sequences showed by far the largest mean genetic
distance (2.38%), with a maximum distance of 4.49%
(DQ408305 and NC_004295). Genotype 3 has been found in
France (13), Brazil (11), the United Kingdom (3), the United
States (FJ265736 [unpublished data]), and foreigners in Ger-
many (12), and it was the most prevalent genotype in Ghana
(2). Interestingly, three of our five sequences from Nigeria and
all five sequences from Burkina Faso also belonged to this
genotype (Fig. 1b). Despite the limited number of sequences,
this may suggest a wider distribution and a predominance of
this genotype in West Africa. Besides the two single sequences
from Bulgaria and Greece, four sequences from Osh in Kyr-
gyzstan also belonged to genotype 3 (Fig. 1b). These sequences
were associated with each of the three clusters of genotype 3b,
covering the full range of genetic variability currently observed
within this subtype. Subtype 3b viruses were all collected
and/or reported during the last decade. They were found in
three different non-African countries in our study as well as
recently in Brazil (4) and in foreigners from North Africa and
Turkey living in Germany (12). This indicates either that 3b
viruses are spreading outside of Africa, or they were previously
missed due to the diagnostic problems mentioned before (1, 5).
In contrast, subtype 3a viruses were only found in Burkina
Faso, and they all belonged to cluster 1 of this subtype.
Mutation rates of B19V are high for a DNA virus and
comparable to those of RNA viruses (8, 14). Within the 994-nt
region, genotype 3 is by far the most diverse, with a mean
intragenotype distance of 2.38%, followed by genotypes 2
FIG. 1—Continued.
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(1.17%) and 1 (0.91%). Although these percentages may be
biased by many identical or very similar genotype 1 sequences,
they indicate that genotype 3 has a longer evolutionary history
than the other two genotypes and that genotype 1 may be of a
more recent origin (8). This hypothesis is also supported by our
finding that very similar genotype 1 viruses circulate widely
throughout Europe and Israel (topmost cluster in Fig. 1b).
In conclusion, this study provides genotype information for
11 countries in Europe, Asia, and West Africa and doubles the
number of B19V sequences spanning the NS1/VP1-unique re-
gion junction available in GenBank. While the worldwide pre-
dominance of genotype 1 and the disappearance of genotype 2
have been confirmed, genotype 3 seems to be more widely
distributed than previously thought. The latter genotype seems
to be predominant in parts of West Africa and has now also
been found in three additional non-African countries.
Whether the recent reports of genotype 3b viruses are due to
improved diagnostics or whether this subtype shows an increas-
ing spread also outside of Africa deserves further investigation.
The high genetic diversity of genotype 3 viruses with several
clusters within subtypes 3a and 3b compared to genotype 1 and
2 viruses is indicative of a longer evolutionary history, probably
in Africa.
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